Personal information

Other IDs

ResearcherID: ACO-1284-2022

Activities

Collapse all

Employment (3)

Peking University Shenzhen Hospital: Shenzhen, Guangdong, CN

2016-11-01 to present | Associate physician (Oncology)
Employment
Source: Self-asserted source
Fen Wang

Peking University Shenzhen Hospital: Shenzhen, Guangdong, CN

2005-05-01 to 2016-11-01 | Attending physician (Oncology)
Employment
Source: Self-asserted source
Fen Wang

Peking University Shenzhen Hospital: Shenzhen, Guangdong, CN

2001-07-01 to 2009-05-01 | Resident physician (Oncology)
Employment
Source: Self-asserted source
Fen Wang

Education and qualifications (3)

Southern Medical University: Guangzhou, Guangdong, CN

2019-09-01 to present | Doctor of Medicine (Oncology)
Education
Source: Self-asserted source
Fen Wang

Peking University: Beijing, Beijing, CN

2009-09-01 to 2011-06-30 | Mater of Medicine (Oncology)
Education
Source: Self-asserted source
Fen Wang

Tongji Medical College: Wuhan, Hubei, CN

1996-09-01 to 2001-06-30 | Bachelor of Medicine (Clinical Medicine)
Education
Source: Self-asserted source
Fen Wang

Works (6)

SOX8 promotes tumor growth and metastasis through FZD6-dependent Wnt/β-catenin signaling in colorectal carcinoma

Heliyon
2023-12 | Journal article
DOI: 10.1016/j.heliyon.2023.e22586
Contributors: Chen Li; Boran Cheng; Xiaodong Yang; Gangling Tong; Fen Wang; Mengqing Li; Xiangyu Wang; Shubin Wang
Source: check_circle
Crossref

Adipocyte-derived CCDC3 promotes tumorigenesis in epithelial ovarian cancer through the Wnt/ß-catenin signalling pathway

Biochemistry and Biophysics Reports
2023-09 | Journal article
DOI: 10.1016/j.bbrep.2023.101507
Contributors: Fen Wang; Feng Jin; Shanshan Peng; Chen Li; Li Wang; Shubin Wang
Source: check_circle
Crossref

Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer

Journal of the National Cancer Center
2022-12 | Journal article
DOI: 10.1016/j.jncc.2022.10.002
Contributors: Fen Wang; Mingyi Yang; Weichi Luo; Qing Zhou
Source: check_circle
Crossref

The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer

Journal of Cancer Research and Clinical Oncology
2022-07 | Journal article
DOI: 10.1007/s00432-021-03752-x
Contributors: Fen Wang; Feng Jin; Boran Cheng; Yue Zhang; Qing Zhou; Shubin Wang
Source: check_circle
Crossref

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma

Journal for ImmunoTherapy of Cancer
2022-01 | Journal article
DOI: 10.1136/jitc-2021-003534
Contributors: Lei Yang; Yun-Ting He; Song Dong; Xue-Wu Wei; Zhi-Hong Chen; Bo Zhang; Wei-Dong Chen; Xiao-Rong Yang; Fen Wang; Xue-Meng Shang et al.
Source: check_circle
Crossref

The Real-World Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer

2021-03-11 | Preprint
DOI: 10.21203/rs.3.rs-282608/v1
Contributors: Fen Wang; Feng Jin; Boran Cheng; Yue Zhang; Qing Zhou; Shubin Wang
Source: check_circle
Crossref

Peer review (26 reviews for 6 publications/grants)

Review activity for Cancer medicine. (1)
Review activity for Journal of chemotherapy (5)
Review activity for Journal of thoracic disease. (1)
Review activity for Journal of thoracic oncology. (11)
Review activity for JTO clinical and research reports. (5)
Review activity for World journal of surgical oncology (3)
How many people are using ORCID?